Soft tissue sarcomas are rare cancers commonly affecting the limbs. In most patients, treatment involves surgical removal of the cancer. Isolated limb perfusion (ILP) is a surgical technique that may be used when patients have a large tumours or had previous surgery. ILP delivers high-dose anti-cancer drugs to an affected limb whilst avoiding life-threatening side effects throughout the body. Research has found that adding cancer-killing viruses to ILP (OV-ILP) improved how long the treatment kept the tumour from growing, neither ILP or OV-ILP treatment prevent tumour spread.
The immune system plays a major role in the development of cancer, with many tumours able to switch off the immune system from attacking tumour cells.
This project looks at whether standard ILP and OV-ILP alters the number and type of immune cells within a tumour. It will also look at whether combining OV-ILP with other drugs that activate the immune system is an effective strategy to treat or prevent tumour spread in patients with extremity soft tissue sarcoma.